

# Efgartigimod alfa and hyaluronidase-qvfc inj,soln (VYVGART HYTRULO) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Criteria for Use January 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

## Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive efgartigimod alfa:

- Sensory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ^1
- Concomitant therapy with other monoclonal antibody therapy
- Immunoglobulin therapy or plasma exchange within 1 month
- Serum IgG level less than 600 mg/dL
- Active, untreated infection

## Inclusion Criteria

All of the following must be met:

- Care provided by a VA/VA Community Care neurologist or locally designated expert
- Diagnosis of typical CIDP or any CIDP variant except sensory CIDP ^1
- Inflammatory neuropathy cause and treatment (INCAT) score of 2 or more ^2
- Contraindication, intolerance, or inadequate symptom control after a minimum 3-month trial of each: corticosteroids and immunoglobulins ^3

## Footnotes

1. Different CIDP phenotypes are described in the 2021 European Academy of Neurology guidelines ([Eur J Neurol. 2021;28:3556–3583](#)).
2. INCAT score available at: [Ann Neurol. 2001 Aug;50\(2\):195-201](#)
3. Plasma exchange may count as one of the two required trials.

---

Prepared: January 2025 Contact: N. Antonovich Pharm D, BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)

---